NONMEM Users Network Archive

Hosted by Cognigen

[NMusers] Pharmacometrics Positions at Various Levels of Experience - Boehringer Ingelheim

From: <>
Date: Mon, 3 Apr 2017 18:45:32 +0000

Boehringer Ingelheim (BI) is expanding its global Pharmacometrics (PMx) gro=
up in Biberach, Germany and Ridgefield, CT.

As a pharmacometrician with BI you act as a standing member in early and la=
te phase clinical drug development teams working closely together with expe=
rts in the fields of medicine, clinical pharmacology, biomarker, clinical d=
evelopment, and statistics. Pharmacometricians with the necessary experienc=
e and skill set will have the opportunity to act as leader ("integrator") o=
f those Early Clinical Development Teams and Clinical Pharmacology and Biom=
arker Teams.
In addition to your role as a Project Pharmacometrician supporting one or m=
ultiple projects, BI PMx offers two career development tracks (focus areas)=
. One of them focuses on strategic PMx support of clinical drug development=
 programs (i.e., model-informed drug discovery and development (MID3)). The=
 other one focuses on methodological and technical PMx work (i.e., performi=
ng hands-on PMx analysis and developing and evaluating new PMx approaches a=
nd methods).

Pharmacometricians are assigned to drug development projects approximately =
two years before first-in-man clinical trials and support projects until su=
ccessful regulatory approval and beyond. BI PMx applies a question-based fi=
t-for-purpose approach to inform drug development with state-of-the-art PMx=
 approaches that include but are not limited to non-linear mixed effects mo=
dels, physiological-based pharmacokinetic models, and quantitative systems =
pharmacology models.

Links USA:

Link Germany:

Tasks & Responsibilities

* Development and implementation of a model-informed drug discovery=
 and development (MID3) strategy for clinical drug development projects

* Planning, execution, and reporting of a wide variety of pharmacom=
etric analyses on a clinical trial and clinical drug development project le=

* Development and implementation of innovative pharmacometrics appr=
oaches for supporting decision making in clinical drug development and regu=
latory approval including but not limited to non-linear mixed effects model=
s, physiological-based pharmacokinetic models, and quantitative systems pha=
rmacology models

* Leading a team of pharmacometricians, Early Clinical Development =
Teams, or Clinical Pharmacology and Biomarker Teams


* PhD in Medicine, Pharmaceutics, Mathematics, Statistics, Systems =
Pharmacology, Biology or equivalent area of focus with experience in pharma=
cometrics in pre-clinical or clinical drug development (pharmaceutical indu=
stry, academia or regulatory agency)

* Demonstrated competence with relevant data analysis software such=
 as NONMEM, Monolix, R, SAS, MATLAB, PBPK software, SimBiology.

* Proficient knowledge in clinical pharmacology and model informed =
drug discovery and development

* For Senior Level Positions:

o Demonstrated consistent high quality MID3 contributions to clinical dru=
g development projects at different phases of clinical drug development (st=
rategic and operational)

o Successful track record of managing and developing direct reports

If you have questions, please do not hesitate to contact,

Recruiting Services, Germany, Biberach: Agnes Woyke, Email: agnes.woyke_at_boe=<>

Director Pharmacometrics, USA, Ridgefield: Benjamin Weber, Email: benjamin.=<mailto:benjamin.weber_at_boehringer-ingelheim.c=


Benjamin Weber, PhD
Director, Pharmacometrics
Translational Medicine & Clinical Pharmacology
Boehringer Ingelheim Pharmaceuticals, Inc.
Ridgefield, Connecticut
P: 203-791-6240<mailto:benjamin.weber_at_boehringer-in=>
/LO4tAP> [icon-youtube.gif] <>

CONFIDENTIALITY NOTICE: This e-mail message, including any attachments, is =
for the sole use of the intended recipient(s) and may contain confidential =
and privileged information. Any unauthorized review, use, disclosure of dis=
tribution is prohibited. If you are not the intended recipient, please con=
tact sender by reply e-mail and destroy all copies of the original message.

(image/png attachment: image001.png)

(image/gif attachment: image002.gif)

(image/gif attachment: image003.gif)

(image/gif attachment: image004.gif)

Received on Mon Apr 03 2017 - 14:45:32 EDT

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to: Once subscribed, you may contribute to the discussion by emailing: